Mauna Kea Technologies is well positioned on the stock market this Tuesday, following the publication of positive results from a pneumopathy trial.

According to the data, published in the peer-reviewed journal Respiration, the Cellvizio platform is more accurate and safer than X-ray fluoroscopy in guiding transbronchial cryobiopsy, enabling improved diagnosis of diffuse interstitial lung disease.

The study - carried out on 80 patients between January and November 2022 - shows a significantly higher rate of diagnosis (95% vs. 80%), as well as a 30% reduction in operating time, a 45% reduction in bleeding and, in particular, a much lower incidence of pneumothorax (0% vs. 25%), compared with the group using fluoroscopy.

Listed on the Paris Bourse, Mauna Kea shares gained 2% on Tuesday following the publication of these data.

Copyright (c) 2023 All rights reserved.